Agmatine Sulfate

Endogenous arginine metabolite with a multi-receptor footprint — modest NMDA antagonism (GluN2B-preferring), imidazoline I1/I2 + alpha-2 agonism, and eNOS enhancement. Best human evidence is for neuropathic pain (B-tier RCT in lumbar radiculopathy at 2.67 g/day). Animal evidence is robust for opioid-tolerance prevention, anxiolysis, and depression potentiation; human evidence on those is thin. For Dylan: cheap, daily-safe, plausible 4-in-1 hedge (calm + pump + pain modulation + stim-tolerance ceiling raise). OPTIONAL-ADD with 4-6 week trial.

Agmatine is what your body makes when arginine decarboxylase (ADC) chops the carboxyl group off L-arginine. It sits in a small mitochondrial pool of neurons and astrocytes, gets degraded by agmatinase into putrescine (entering the polyamine pathway) or by diamine oxidase. Endogenously it functions as a neuromodulator with no clean single-receptor identity.

The receptor footprint that matters:

1. NMDA receptor antagonism (modest, subunit-selective). Agmatine preferentially blocks GluN2B-containing NMDA receptors at the spinal cord level. This is the same subtype targeted by ketamine, memantine, and lanicemine, but agmatine's affinity is much lower — it does not produce dissociation or cognitive blunting at oral doses. The GluN2B selectivity is therapeutically attractive: GluN2B drives excitotoxicity and chronic-pain sensitization, while GluN2A handles physiological signaling.

2. nNOS / iNOS inhibition + eNOS enhancement. Agmatine downregulates neuronal NOS (nNOS, the one that drives glutamate-induced excitotoxicity) and inducible NOS (iNOS, the inflammatory form), while raising endothelial NOS (eNOS, the vasodilation-driving form). Net effect: better vascular blood flow, less neural inflammation. This is the basis for both the pre-workout pump claim and the neuroprotection claim.

3. Imidazoline I1/I2 receptor agonism. Agmatine is considered an endogenous ligand for imidazoline receptors. I1 receptor activation in the medial habenula → decreased excitation of the interpeduncular nucleus → increased midbrain dopaminergic function. This is the proposed locus for the antidepressant effect. I1 antagonist efaroxan abolishes agmatine's antidepressant-like effects in animals; the alpha-2 antagonist yohimbine does not — so the mood angle is more imidazoline than alpha-2.

4. Alpha-2 adrenergic agonism. Lower-affinity than its imidazoline binding, but relevant for opioid potentiation (yohimbine blocks agmatine's morphine-potentiating effect) and for some of the calming effects.

5. Polyamine pathway intermediate. Putrescine → spermidine → spermine. Agmatine also competitively inhibits polyamine transport and induces SSAT (spermidine/spermine acetyltransferase). Translation: it acts as a partial buffer/regulator of polyamine flux, which matters for cell growth, autophagy, and BDNF signaling. Practical relevance to humans is unclear.

Pharmacokinetics: Oral bioavailability ~29-35% (rat data — no clean human BA studies). Plasma half-life 2 hours after oral dosing. Crosses blood-brain barrier. Renally cleared (unmetabolized fraction). The short half-life is why pain protocols use 3× daily dosing.